Sangamo Therapeutics (NASDAQ:SGMO) shares traded -3.66% down during most recent session to reach at the closing price of $9.73. The stock exchanged hands 1.13 Million shares versus average trading capacity of 2.17 Million shares, yielding a market cap of $995.08 Million. Wall Street analysts covering the stock are projecting that the stock will reach $18.71 within the next 52-weeks. The mean target projections are based on 7 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Sangamo Therapeutics (NASDAQ:SGMO) high price target of $30 and with a conservative view have low price target of $10.

JP Morgan “Maintained” Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued to investors on 11/14/18 to Neutral with price target of $11.

Additionally on 11/14/18 JP Morgan “Downgrades” Sangamo Therapeutics (NASDAQ:SGMO) to Neutral setting price target at $11 and on 11/09/18 Guggenheim “Downgrades” the stock to Neutral at $0. Furthermore on 6/20/18 Bank of America “Initiates Coverage On” the stock to Buy at $24.

On the other hand the company has Relative Strength Index (RSI 14) of 49.74 along with Average True Range (ATR 14) of 0.72, Consequently Sangamo Therapeutics (NASDAQ:SGMO)’s weekly and monthly volatility is 4.78%, 6.05% respectively. The company’s beta value is at 2.78.

In terms of Buy, Sell or Hold recommendations, Sangamo Therapeutics (NASDAQ:SGMO) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Sangamo Therapeutics (NASDAQ:SGMO)’s minimum EPS for the current quarter is at $-0.37 and can go high up to $-0.16. The consensus mean EPS for the current quarter is at $-0.25 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.23 earnings per share for the same quarter during last year.

Previously Sangamo Therapeutics (NASDAQ:SGMO) reported $-0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.21 by $0.03. The company posted an earnings surprise of 14.3%.

Sangamo Therapeutics (NASDAQ:SGMO)’s revenue estimates for the current quarter are $22.8 Million according to 4 number of analysts, for the current quarter the company has high revenue estimates of $30.2 Million in contradiction of low revenue estimates of $12.5 Million. For the current year the company’s revenue estimates are $95.29 Million compared to low analyst estimates of $50 Million and high estimates of $122.9 Million according to 8 number of analysts.

Currently Sangamo Therapeutics (NASDAQ:SGMO)’s shares owned by insiders are 0.2%, whereas shares owned by institutional owners are 63.7%. However the six-month change in the insider ownership was recorded -19.01%, as well as three-month change in the institutional ownership was recorded -0.47%.

Sangamo Therapeutics (NASDAQ:SGMO)’s trailing twelve month revenues are $84.5 Million, whereas its price to sales ratio for the same period is 11.78. Its book value per share for the most recent quarter is $3.58 while its price to book ratio for the same period is 2.72, as for as the company’s cash per share for the most recent quarter is $3.91, however its price to cash per share ratio for the same period is 2.49. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.